These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

422 related items for PubMed ID: 26887034

  • 1. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K, Yang J, Aisenberg J, Wright N, Kaplowitz P, Lahlou N, Linares J, Lundström E, Purcea D, Cassorla F.
    J Pediatr Endocrinol Metab; 2016 Nov 01; 29(11):1241-1248. PubMed ID: 26887034
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study.
    Luo X, Zhang C, Yang Y, Xu X, Cheng X, Wei H, Wang L, Huang F, Shi X, Cabri P.
    Adv Ther; 2023 Oct 01; 40(10):4574-4588. PubMed ID: 37584898
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.
    Martínez-Aguayo A, Hernández MI, Beas F, Iñiguez G, Avila A, Sovino H, Bravo E, Cassorla F.
    J Pediatr Endocrinol Metab; 2006 Aug 01; 19(8):963-70. PubMed ID: 16995580
    [Abstract] [Full Text] [Related]

  • 8. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
    Liang Y, Wei H, Zhang JL, Hou L, Luo XP.
    Zhonghua Er Ke Za Zhi; 2004 Nov 01; 42(11):845-9. PubMed ID: 15631714
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
    Zenaty D, Blumberg J, Liyanage N, Jacqz-Aigrain E, Lahlou N, Carel JC, Co-Investigators.
    Horm Res Paediatr; 2016 Nov 01; 86(3):188-195. PubMed ID: 27603324
    [Abstract] [Full Text] [Related]

  • 11. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
    Salerno M, Di Maio S, Gasparini N, Mariano A, Macchia V, Tenore A.
    Horm Res; 1998 Nov 01; 50(4):205-11. PubMed ID: 9838241
    [Abstract] [Full Text] [Related]

  • 12. Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation
.
    Durand A, Tauber M, Patel B, Dutailly P.
    Horm Res Paediatr; 2017 Nov 01; 87(4):224-232. PubMed ID: 28334719
    [Abstract] [Full Text] [Related]

  • 13. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M, Chaussain JL, Berlier P, Bost M, Canlorbe P, Colle M, Francois R, Garandeau P, Lahlou N, Morel Y.
    J Clin Endocrinol Metab; 1986 Apr 01; 62(4):670-7. PubMed ID: 2936759
    [Abstract] [Full Text] [Related]

  • 14. A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty.
    Yu X, Cheng X, Wei H, Xu X, Gong C, Li G, Yao H, Zhou L, Zhong Y, Yang Y, Luo F, Zhang Y, Huang F, Shi X, Cabri P, Luo X.
    Adv Ther; 2024 Oct 16. PubMed ID: 39412628
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of subcutaneous administration of gonadotropin-releasing hormone agonist on idiopathic central precocious puberty.
    Liang Y, Wei H, Zhang J, Hou L, Luo X.
    J Huazhong Univ Sci Technolog Med Sci; 2006 Oct 16; 26(5):558-61. PubMed ID: 17219967
    [Abstract] [Full Text] [Related]

  • 16. Assessment of Estradiol Response after Depot Triptorelin Administration in Girls with Central Precocious Puberty.
    Freire AV, Gryngarten MG, Ballerini MG, Arcari AJ, Escobar ME, Bergadá I, Ropelato MG.
    Horm Res Paediatr; 2016 Oct 16; 85(1):58-64. PubMed ID: 26675317
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, Mattia-Goldberg C, Chwalisz K.
    J Clin Endocrinol Metab; 2012 May 16; 97(5):1572-80. PubMed ID: 22344198
    [Abstract] [Full Text] [Related]

  • 18. Central precocious puberty: treatment with triptorelin 11.25 mg.
    Chiocca E, Dati E, Baroncelli GI, Cassio A, Wasniewska M, Galluzzi F, Einaudi S, Cappa M, Russo G, Bertelloni S.
    ScientificWorldJournal; 2012 May 16; 2012():583751. PubMed ID: 22645436
    [Abstract] [Full Text] [Related]

  • 19. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
    Garibaldi LR, Aceto T, Weber C, Pang S.
    J Clin Endocrinol Metab; 1993 Apr 16; 76(4):851-6. PubMed ID: 8473395
    [Abstract] [Full Text] [Related]

  • 20. Central precocious puberty in girls: Diagnostic study and auxological response to triptorelin treatment.
    Durá-Travé T, Ortega Pérez M, Ahmed-Mohamed L, Moreno-González P, Chueca Guindulain MJ, Berrade-Zubiri S.
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Apr 16; 66(7):410-416. PubMed ID: 30808564
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.